A Targetable Bone Marrow-Niche Axis for the Treatment of Acute Myeloid Leukemia

Converging lines of evidence show that the endosteal niche within the bone marrow (BM) microenvironment plays a crucial role in the pathogenesis and chemoresistance of myeloid malignancies. Dysplastic cells can exploit niche-dependent, cell non-autonomous pathways to favor their growth. Molecular delineation and targeting of those pathways may help overcome resistance to targeted therapies. In particular, acute myeloid leukemia (AML) remains recalcitrant to conventional chemo- and targeted-therapies leading to relapse and low overall survival rates (5-year survival rate <30%). These shortcomings highlight the urgency of proposing novel and adapted therapies for the disease. Leveraging genetic mouse models, patient-derived xenografts (PDX), and patient samples, herein we show the mechanism and therapeutic targeting of a cell non-autonomous progression pathway in AML. Specifically, we show that conditional ablation of serotonin receptor 1b (HTR1B) in osteoblasts -during or after AML engraftment- hampers or even prevents AML progression, increasing overall survival. Mass spectrometry-based untargeted metabolomics identified the tryptophan catabolite kynurenine (Kyn) as an oncometabolite secreted by AML cells. Remarkably, the AML proliferative pathway that exploits peripheral serotonin signaling in osteoblasts, is not driven by serotonin but by Kyn, which acts as a previously unrecognized HTR1B ligand. To explore in vivo the significance of Kyn for leukemia progression, we inhibited its synthesis by suppressing indoleamine 2,3-dioxygenase-1 (IDO1) activity in mouse and human AML cells. CRISPR-Cas9-mediated Ido1 targeting suppressed AML growth in a dose-dependent manner. Next, we sought to identify the downstream molecular targets of Kyn in human osteoblasts that render the BM niche permissive to AML engraftment and support proliferation of leukemia cells. RNAseq analysis of co-cultures between primary human osteoblasts and leukemia cells shows that AML cells induce a pro-inflammatory remodeling of the osteoblastic niche that depends on HTR1B engagement by Kyn. Among the plethora of secreted pro-inflammatory molecules induced in osteoblasts, AML-secreted Kyn (but not the canonical HTR1B ligand serotonin) induces secretion of the acute-phase protein serum amyloid-A (SAA), which in turn acts in a positive feedback-loop on leukemia cells by increasing IDO1 expression, the rate-limiting enzyme for Kyn synthesis. Acting in an autocrine manner -in a mode distinct from its established immunomodulatory properties in cancer- Kyn activates the aryl hydrocarbon receptor (AHR), thereby supporting further AML proliferation. Highlighting a clinical relevance of these findings, the Kyn-HTR1B-SAA-IDO1 AML-promoting axis identified in leukemia mouse models, is recapitulated in PDX as well as myelodysplastic syndromes (MDS) and AML patients. Preferential and progressive production of Kyn over serotonin by leukemic cells, as well as increased levels of SAA1 in the BM plasma, occur as the disease pathogenesis proceeds from MDS to AML in patients. Moreover, genetic or pharmacological (Epacadostat) IDO1 inhibition hinders AML progression in PDX models. Of note, inhibition of IDO1 synergizes with chemotherapy to reduce AML burden. Overall, these data suggest that the leukemia-osteoblast crosstalk conferred by the Kyn-HTR1B-SAA-IDO1 axis has potential as a therapeutic target. This niche-dependent, cell non-autonomous AML axis, may impact the management of myeloid malignancies, opening also new opportunities for cancer treatment in conjunction with chemo/immunotherapies. Disclosures Borot: Vor Biopharma: Consultancy, Patents & Royalties: coinventor on issued and pending patent applications licensed to Vor Biopharm. Ali: Vor Biopharma: Consultancy, Patents & Royalties: coinventor on issued and pending patent applications licensed to Vor Biopharm. Roth: UNC: Patents & Royalties: UNC has licensed a patent with B.L.R. listed as an inventor on biased opioid compounds. . Mukherjee: Vor Biopharma: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: coinventor on issued and pending patent applications licensed to Vor Biopharma. S.M. has equity ownership and is on the Scientific Advisory Board of Vor Biopharma., Research Funding. Rabadan: AimedBio: Membership on an entity's Board of Directors or advisory committees; Genotwin: Other: Raul Rabadan is founder of Genotwin. Carroll: Incyte Pharmaceuticals: Research Funding; Janssen Pharmaceutical: Consultancy. Raza: Celgene Inc: Research Funding, Speakers Bureau; Novartis: Speakers Bureau; Genoptix: Speakers Bureau; Kura Oncology: Research Funding; Janssen R&D: Research Funding; Syros Pharmaceuticals: Research Funding; Onconova Therapeutics: Research Funding, Speakers Bureau.

DCAF1-targeting microRNA-3175 activates Nrf2 signaling and inhibits dexamethasone-induced oxidative injury in human osteoblasts

Activation of nuclear-factor-E2-related factor 2 (Nrf2) signaling can protect human osteoblasts from dexamethasone-induced oxidative injury. DDB1 and CUL4 associated factor 1 (DCAF1) is a novel ubiquitin E3 ligase for Nrf2 protein degradation. We identified a novel DCAF1-targeting miRNA, miR-3175. RNA pull-down, Argonaute 2 RNA-immunoprecipitation, and RNA fluorescent in situ hybridization results confirmed a direct binding between miR-3175 and DCAF1 mRNA in primary human osteoblasts. DCAF1 3′-untranslated region luciferase activity and its expression were significantly decreased after miR-3175 overexpression but were augmented with miR-3175 inhibition in human osteoblasts and hFOB1.19 osteoblastic cells. miR-3175 overexpression activated Nrf2 signaling, causing Nrf2 protein stabilization, antioxidant response (ARE) activity increase, and transcription activation of Nrf2-dependent genes in human osteoblasts and hFOB1.19 cells. Furthermore, dexamethasone-induced oxidative injury and apoptosis were largely attenuated by miR-3175 overexpression in human osteoblasts and hFOB1.19 cells. Importantly, shRNA-induced silencing or CRISPR/Cas9-mediated Nrf2 knockout abolished miR-3175 overexpression-induced osteoblast cytoprotection against dexamethasone. Conversely, DFAC1 knockout, by the CRISPR/Cas9 method, activated the Nrf2 cascade and inhibited dexamethasone-induced cytotoxicity in hFOB1.19 cells. Importantly, miR-3175 expression was decreased in necrotic femoral head tissues of dexamethasone-taking patients, where DCAF1 mRNA was upregulated. Together, silencing DCAF1 by miR-3175 activated Nrf2 signaling to inhibit dexamethasone-induced oxidative injury and apoptosis in human osteoblasts.

Phosphoglycerate kinase 1 silencing by a novel microRNA microRNA-4523 protects human osteoblasts from dexamethasone through activation of Nrf2 signaling cascade

Nuclear-factor-E2-related factor 2 (Nrf2) cascade activation can ameliorate dexamethasone (DEX)-induced oxidative injury and death in human osteoblasts. Phosphoglycerate kinase 1 (PGK1) depletion is shown to efficiently activate Nrf2 signaling by inducing methylglyoxal modification of Kelch-like ECH-associated protein 1 (Keap1). We here identified a novel PGK1-targeting microRNA: microRNA-4523 (miR-4523). RNA fluorescent in situ hybridization, RNA pull-down, and Argonaute-2 RNA immunoprecipitation results confirmed a direct binding between miR-4523 and PGK1 mRNA in primary human osteoblasts and hFOB1.19 osteoblastic cells. Forced overexpression of miR-4523, using a lentiviral construct, robustly decreased PGK1 3′-UTR (untranslated region) luciferase activity and downregulated its expression in human osteoblasts and hFOB1.19 cells. Furthermore, miR-4523 overexpression activated the Nrf2 signaling cascade, causing Keap1–Nrf2 disassociation, Nrf2 protein stabilization, and its nuclear translocation as well as transcription activation of Nrf2-dependent genes (NQO1, GCLC, and HO1) in human osteoblasts. By expressing a UTR-null PGK1 construct, miR-4523 overexpression-induced Nrf2 cascade activation was however largely inhibited. Importantly, DEX-induced reactive oxygen species production, oxidative injury, and cell apoptosis were significantly attenuated by miR-4523 overexpression in human osteoblasts and hFOB1.19 cells. Such actions by miR-4523 were abolished by Nrf2 shRNA or knockout, but mimicked by PGK1 knockout (using CRISPR/Cas9 method). In PGK1 knockout human osteoblasts, miR-4523 overexpression failed to further increase Nrf2 cascade activation and offer osteoblast cytoprotection against DEX. Significantly, miR-4523 is downregulated in human necrotic femoral head tissues of DEX-taking patients. Together, PGK1 silencing by miR-4523 protected human osteoblasts from DEX through activation of the Nrf2 signaling cascade.

Cytotoxicity of Ti/SS316/Mg Particles on Human Osteoblasts

Daily walking or exercise of the bone implant recipients may generate particles due to wear and tear. Reports have mentioned that particles could circulate in the human body and trigger aseptic loosening, inflammation, and other potential complications. The mechanism of these phenomena remains mostly unclear. This study is to investigate the cytotoxicity of titanium (Ti), stainless steel 316 (SS316), and magnesium (Mg) particles due to these materials are the most commonly used biomaterials based on their adequate mechanical properties and excellent biocompatibility. Human osteoblasts (SAOS2 cells) were exposed directly to different concentrations of Ti/SS316/Mg particle during the direct cytotoxicity test. Together with the previous study, we found out that Ti particles showed cytotoxicity to osteoblasts at different dosages and times, while SS316 particles and Mg particles (low dosage) can reduce the cytotoxicity induced by Ti particles and boost cell viability. Mg particles can be toxic to osteoblast at a higher dosage, while SS316 particles are “safer” than Mg particles at higher dosages. Cell viability and cell morphology of SAOS2 cells under different treatments were observed at 2/3/5 days. This study found out that cell viability could be enhanced with certain combinations of Ti/SS316/Mg particles. This can give us certain guideline on how to design and fabricate a hybrid bone implant. However, how to quantify the particles inside the human body in real-time, and the exact interaction among particles, cells, tissues, and even organs require further research.

New Sintered Porous Scaffolds of Mg,Sr Co-Substituted Hydroxyapatite Support Growth and Differentiation of Primary Human Osteoblasts In Vitro

Strontium (Sr) and Magnesium (Mg) are bioactive ions that have been proven to exert a beneficial effect on bone; therefore, their incorporation into bone substitutes has long been viewed as a possible approach to improve tissue integration. However, the thermal instability of Mg-substituted hydroxyapatites has hitherto limited development. We previously described the creation of thermally consolidated porous constructs of Mg,Sr co-substituted apatites with adequate mechanical properties for their clinical use. The present paper describes the biocompatibility of Mg,Sr co-substituted granules using an alveolar-bone-derived primary model of human osteoblasts. Cells were cultured in the presence of different amounts of hydroxyapatite (HA), Sr-substituted HA, or MgSrHA porous macrogranules (with a size of 400–600 microns, obtained by grinding and sieving the sintered scaffolds) for three and seven days, and their viability was measured by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Protein content was measured using the Lowry assay at the same time points. Cell viability was not impaired by any of the tested compounds. Indirect and direct biocompatibility of these macrogranules was assessed by culturing cells in a previously conditioned medium with HA, SrHA, or MgSrHA, or in the presence of material granules. Osteoblasts formed larger and more numerous nodules around SrHA or MgSrHA granules. Furthermore, cell differentiation was evaluated by alkaline phosphatase staining of primary cells cultured in the presence of HA, SrHA, or MgSrHA granules, confirming the increased osteoconductivity of the doped materials.

Detecting respiratory chain deficiency in osteoblasts of older patients

Mitochondria contain their own genome which encodes 13 essential mitochondrial proteins and accumulates somatic variants at up to 10 times the rate of the nuclear genome. These mitochondrial genome variants lead to respiratory chain deficiency and cellular dysfunction. Work with the PolgAmut/PolgAmut mouse model, which has a high mitochondrial DNA mutation rate, showed enhanced levels of age related osteoporosis in affected mice along with respiratory chain deficiency in osteoblasts. To explore whether respiratory chain deficiency is also seen in human osteoblasts with age, we developed a protocol and analysis framework for imaging mass cytometry (IMC) in bone tissue sections to analyse osteoblasts in situ. We have demonstrated significant increases in complex I deficiency with age in human osteoblasts. This work is consistent with findings from the PolgAmut/PolgAmut mouse model and suggests that respiratory chain deficiency, as a consequence of the accumulation of age related mitochondrial DNA mutations, may have a significant role to play in the pathogenesis of human age related osteoporosis.

Human osteoblasts obtained from distinct periarticular sites demonstrate differences in biological function in vitro

Aims Accumulated evidence indicates that local cell origins may ingrain differences in the phenotypic activity of human osteoblasts. We hypothesized that these differences may also exist in osteoblasts harvested from the same bone type at periarticular sites, including those adjacent to the fixation sites for total joint implant components. Methods Human osteoblasts were obtained from the acetabulum and femoral neck of seven patients undergoing total hip arthroplasty (THA) and from the femoral and tibial cuts of six patients undergoing total knee arthroplasty (TKA). Osteoblasts were extracted from the usually discarded bone via enzyme digestion, characterized by flow cytometry, and cultured to passage three before measurement of metabolic activity, collagen production, alkaline phosphatase (ALP) expression, and mineralization. Results Osteoblasts from the acetabulum showed lower proliferation (p = 0.034), cumulative collagen release (p < 0.001), and ALP expression (p = 0.009), and produced less mineral (p = 0.006) than those from the femoral neck. Osteoblasts from the tibia produced significantly less collagen (p = 0.021) and showed lower ALP expression than those from the distal femur. Conclusion We have demonstrated for the first time an anatomical regional variation in the biological behaviours of osteoblasts on either side of the hip and knee joint. The lower osteoblast proliferation, matrix production, and mineralization from the acetabulum compared to those from the proximal femur may be reflected in differences in bone formation and implant fixation at these sites. Cite this article: Bone Joint Res 2021;10(9):611–618.

Nanostructured Surfaces to Promote Osteoblast Proliferation and Minimize Bacterial Adhesion on Titanium

The objective of this study was to investigate the potential of titanium nanotubes to promote the proliferation of human osteoblasts and to reduce monomicrobial biofilm adhesion. A secondary objective was to determine the effect of silicon carbide (SiC) on these nanostructured surfaces. Anodized titanium sheets with 100–150 nm nanotubes were either coated or not coated with SiC. After 24 h of osteoblast cultivation on the samples, cells were observed on all titanium sheets by SEM. In addition, the cytotoxicity was evaluated by CellTiter-BlueCell assay after 1, 3, and 7 days. The samples were also cultivated in culture medium with microorganisms incubated anaerobically with respective predominant periodontal bacteria viz. Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia as monoinfection at 37 °C for 30 days. The biofilm adhesion and coverage were evaluated through surface observation using Scanning Electron Microscopy (SEM). The results demonstrate that Ti nanostructured surfaces induced more cell proliferation after seven days. All groups presented no cytotoxic effects on human osteoblasts. In addition, SEM images illustrate that Ti nanostructured surfaces exhibited lower biofilm coverage compared to the reference samples. These results indicate that Ti nanotubes promoted osteoblasts proliferation and induced cell proliferation on the surface, compared with the controls. Ti nanotubes also reduced biofilm adhesion on titanium implant surfaces.